CellMax reports colorectal cancer diagnostic data

CellMax Life Inc. (Sunnyvale, Calif.) reported that its CellMax-CRC colorectal cancer screening test detected colorectal cancer with 84% sensitivity and 97.3% specificity. The single-site, Taiwanese trial enrolled 620 adults who were undergoing a routine colonoscopy or who had adenomatous polyps or early to late-stage colorectal cancer. The study was sponsored by Taiwan's Ministry of Health and Chang Gung Memorial Hospital. The data were released in an abstract ahead of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco...